The search parameters were set as follows: Trypsin/P was specified as the protease with up to 2 missed cleavages permitted
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
Biomarkers like collagen-1C degradation fragments or hyaluronic acid levels may offer context, though specific GHK-Cu response biomarkers remain understudied
Constitutive activation of liver kinase B1/AMP-activated protein kinase (LKB1/AMPK) pathway in KO livers The resistance of KO mice to steatosis induced by chronic EtOH consumption suggests low hepatic GSH elicits a protective metabolic adaption in the liver
Also see the our PDCure.org project to develope a new mercury chelator.